Myeloma idiotype antigen (Id)

The Myeloma idiotype antigen is a tumor-specific antigen derived from the unique variable regions (V-regions) of the monoclonal immunoglobulin, or M-protein, produced by malignant plasma cells in patients with multiple myeloma (Source: National Cancer Institute). Because each patient's malignancy arises from a single transformed B-cell clone, the specific amino acid sequence of the immunoglobulin's variable domain is unique to that individual's tumor, providing a highly specific target for personalized immunotherapy (Source: PubMed, PMID: 11030341). In therapeutic applications, the idiotype is typically isolated from the patient's serum or produced via recombinant technology and used as a vaccine to stimulate the patient's own immune system to recognize and destroy the cancerous cells. To overcome the naturally low immunogenicity of these self-derived proteins, they are often conjugated to potent carrier proteins like Keyhole Limpet Hemocyanin (KLH) and administered alongside adjuvants such as GM-CSF (Source: Journal of Hematology & Oncology). While this approach offers the potential for high specificity with minimal off-target toxicity, its clinical utility has been challenged by the necessity for custom manufacturing for every patient and the risk of tumor escape through clonal evolution.

Other names

Monoclonal immunoglobulin idiotypeM-protein idiotypeTumor-specific idiotypeB-cell receptor idiotypeParaprotein idiotype

Induction of a patient-specific active immune response, primarily through the activation of cytotoxic T lymphocytes and the production of anti-idiotypic antibodies that target the unique variable regions of the monoclonal immunoglobulin expressed by malignant plasma cells (Source: PubMed, PMID: 15133031).